STOKE THERAPEUTICS INC's ticker is STOK and the CUSIP is 86150R107. A total of 90 filers reported holding STOKE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $226,779 | +4.8% | 57,558 | +182.9% | 0.00% | – |
Q2 2023 | $216,289 | +1.7% | 20,347 | -20.3% | 0.00% | – |
Q1 2023 | $212,681 | -7.9% | 25,532 | +2.1% | 0.00% | – |
Q4 2022 | $230,861 | +207.8% | 25,012 | +327.5% | 0.00% | – |
Q3 2022 | $75,000 | -65.1% | 5,851 | -64.2% | 0.00% | – |
Q2 2022 | $215,000 | +18.1% | 16,322 | +89.1% | 0.00% | – |
Q1 2022 | $182,000 | -85.9% | 8,632 | -83.9% | 0.00% | – |
Q4 2021 | $1,289,000 | +502.3% | 53,742 | +540.0% | 0.00% | – |
Q3 2021 | $214,000 | -48.4% | 8,397 | -31.9% | 0.00% | – |
Q2 2021 | $415,000 | -16.5% | 12,323 | -3.8% | 0.00% | – |
Q1 2021 | $497,000 | +126.9% | 12,811 | +263.0% | 0.00% | – |
Q4 2020 | $219,000 | +63.4% | 3,529 | -11.4% | 0.00% | – |
Q3 2020 | $134,000 | -38.5% | 3,983 | -56.5% | 0.00% | – |
Q2 2020 | $218,000 | +62.7% | 9,156 | +56.5% | 0.00% | – |
Q1 2020 | $134,000 | +31.4% | 5,849 | +61.9% | 0.00% | – |
Q4 2019 | $102,000 | +29.1% | 3,613 | -2.7% | 0.00% | – |
Q3 2019 | $79,000 | – | 3,714 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ATP Life Science Ventures, L.P. | 16,786,713 | $562,187,000 | 75.80% |
RTW INVESTMENTS, LP | 3,544,248 | $118,697,000 | 2.86% |
Cormorant Asset Management, LP | 1,537,807 | $51,501,000 | 1.98% |
Redmile Group, LLC | 2,549,506 | $85,383,000 | 1.57% |
Birchview Capital, LP | 40,000 | $1,340,000 | 0.45% |
HighVista Strategies LLC | 17,082 | $572,000 | 0.42% |
Perceptive Advisors | 671,978 | $22,505,000 | 0.33% |
GILDER GAGNON HOWE & CO LLC | 1,490,153 | $49,905,000 | 0.31% |
Artal Group S.A. | 270,750 | $9,067,000 | 0.22% |
VIRTUS ALTERNATIVE INVESTMENT ADVISERS, INC. | 323 | $11,000 | 0.20% |